WVE Valuation

WAVE Life Sciences Ltd

Add to Watchlist

Advanced Chart

8.000

-1.62(-16.840%)1D

Overview
Forecast
Valuation
Earnings

WVE Relative Valuation

WVE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, WVE is overvalued; if below, it's undervalued.

Historical Valuation

WAVE Life Sciences Ltd (WVE) is now in the Overvalued zone, suggesting that its current forward PS ratio of 31.46 is considered Overvalued compared with the five-year average of -4.94. The fair price of WAVE Life Sciences Ltd (WVE) is between 4.38 to 7.75 according to relative valuation methord. Compared to the current price of 7.79 USD , WAVE Life Sciences Ltd is Overvalued By 0.49%.

Relative Value

Fair Zone

4.38-7.75

Current Price：7.79

0.49%

Overvalued

-8.34

Trailing

Forward

-7.04

EV/EBITDA

WAVE Life Sciences Ltd. (WVE) has a current EV/EBITDA of -7.04. The 5-year average EV/EBITDA is -2.19. The thresholds are as follows: Strongly Undervalued below -8.66, Undervalued between -8.66 and -5.43, Fairly Valued between 1.05 and -5.43, Overvalued between 1.05 and 4.28, and Strongly Overvalued above 4.28. The current Forward EV/EBITDA of -7.04 falls within the Undervalued range.

-6.55

EV/EBIT

WAVE Life Sciences Ltd. (WVE) has a current EV/EBIT of -6.55. The 5-year average EV/EBIT is -3.43. The thresholds are as follows: Strongly Undervalued below -9.48, Undervalued between -9.48 and -6.46, Fairly Valued between -0.41 and -6.46, Overvalued between -0.41 and 2.62, and Strongly Overvalued above 2.62. The current Forward EV/EBIT of -6.55 falls within the Undervalued range.

31.46

WAVE Life Sciences Ltd. (WVE) has a current PS of 31.46. The 5-year average PS is 12.80. The thresholds are as follows: Strongly Undervalued below -4.25, Undervalued between -4.25 and 4.28, Fairly Valued between 21.32 and 4.28, Overvalued between 21.32 and 29.84, and Strongly Overvalued above 29.84. The current Forward PS of 31.46 falls within the Strongly Overvalued range.

-8.92

P/OCF

WAVE Life Sciences Ltd. (WVE) has a current P/OCF of -8.92. The 5-year average P/OCF is -6.02. The thresholds are as follows: Strongly Undervalued below -17.42, Undervalued between -17.42 and -11.72, Fairly Valued between -0.33 and -11.72, Overvalued between -0.33 and 5.37, and Strongly Overvalued above 5.37. The current Forward P/OCF of -8.92 falls within the Historic Trend Line -Fairly Valued range.

-8.47

P/FCF

WAVE Life Sciences Ltd. (WVE) has a current P/FCF of -8.47. The 5-year average P/FCF is -5.28. The thresholds are as follows: Strongly Undervalued below -14.19, Undervalued between -14.19 and -9.74, Fairly Valued between -0.83 and -9.74, Overvalued between -0.83 and 3.63, and Strongly Overvalued above 3.63. The current Forward P/FCF of -8.47 falls within the Historic Trend Line -Fairly Valued range.

WAVE Life Sciences Ltd (WVE) has a current Price-to-Book (P/B) ratio of 10.75. Compared to its 3-year average P/B ratio of -35.98 , the current P/B ratio is approximately -129.88% higher. Relative to its 5-year average P/B ratio of -128.86, the current P/B ratio is about -108.34% higher. WAVE Life Sciences Ltd (WVE) has a Forward Free Cash Flow (FCF) yield of approximately -13.09%. Compared to its 3-year average FCF yield of -13.27%, the current FCF yield is approximately -1.33% lower. Relative to its 5-year average FCF yield of -26.23% , the current FCF yield is about -50.08% lower.

10.75

P/B

Median3y

-35.98

Median5y

-128.86

-13.09

FCF Yield

Median3y

-13.27

Median5y

-26.23

Competitors Valuation Multiple

The average P/S ratio for WVE's competitors is 61.91, providing a benchmark for relative valuation. WAVE Life Sciences Ltd Corp (WVE) exhibits a P/S ratio of 31.46, which is -49.18% above the industry average. Given its robust revenue growth of -55.82%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

WVE.O

WAVE Life Sciences Ltd

Edgewise Therapeutics Inc

Loss

1.54B

AUPH.O

Aurinia Pharmaceuticals Inc

Celldex Therapeutics Inc

Immunocore Holdings PLC

Twist Bioscience Corp

3.90

17.91%

1.57B

Performance Decomposition

Market capitalization of WVE increased by 17.32% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -167.19 to -580.17.

The secondary factor is the Revenue Growth, contributed -55.82%to the performance.

Overall, the performance of WVE in the past 1 year is driven by Margin Expansion. Which is more sustainable.

-55.82%

19.69M → 8.70M

Revenue Growth

247.01%

-167.19 → -580.17

Margin Expansion

-173.87%

15.56 → -11.50

P/E Change

17.32%